All News

Lung cancer can be overwhelming, but learning about types, stages, treatments and support can help patients feel more prepared for their care journey.

Prior to my diagnosis with Stage 3B Lung Cancer, I had spent many years reading self-help books. I worked hard, but never felt successful, or took pride in myself.

Recent clinical trial results, real-world safety data, and patient experiences highlight meaningful advances in blood cancer care.

The FDA approved Guardant360 CDx to identify adults with ESR1-mutated, ER-positive, HER2-negative breast cancer eligible for treatment with Inluriyo.

Alison Ankiewicz explains how pelvic physical therapy restores tissue, sexual function and emotional confidence for patients after cancer treatment.

CPAN begins the fourth quarter with a continued focus on its core mission: education.

You don’t want to miss the upcoming CPAN Advocacy Chat, we hope you can join us!

Jennie Smythe, a breast cancer survivor, shared her journey from diagnosis to survivorship in an interview with CURE during Breast Cancer Awareness Month.

A diagnosis of esophageal cancer can bring up many questions and concerns. Our goal is to provide you with clear, accurate and educational information.

Oct. 1, Previvor Day, acknowledges us who carry a hereditary cancer syndrome or genetic mutation that significantly increases our risk of cancer.

Adding Tecentriq to chemoradiation improved quality of life and supported twice-daily radiation for patients with limited-stage small cell lung cancer.

The FDA approved the denosumab biosimilars Enoby and Xtrenbo for patients on hormone therapies for breast or prostate cancer that weaken bones.

Dr. Mary B. Beasley discusses evolving role of pathologists in lung cancer care, highlighting how emerging technologies may shape the future of the field.

Heather Ann Yonker expands on strategies for maintaining food safety in the home, particularly for patients with compromised immune systems due to cancer.

Frank Garred, 77, completed Inlexzo treatment for recurrent bladder cancer, describing it as manageable with minimal side effects compared with BCG.

For patients with cancer grappling with nausea or vomiting due to their treatments, a potential side effect remedy may be found in their own hands.

Penn Medicine researchers found two oral drugs eliminated dormant breast cancer cells in most patients, with relapse rates dropping to about 4% after seven years.

Napo Pharmaceuticals applied for orphan drug designation for Mytesi to treat diarrhea in patients with breast cancer and brain metastases on targeted therapy.

Dr. Edgardo Santos explains that combining Tagrisso with chemotherapy or Leclaza plus Rybrevant may improve survival versus monotherapy alone.

An LED-based intraoral device was safe and reduced severe oral mucositis and throat pain in patients receiving radiotherapy for head and neck cancers.

Tamara Mobley shares how persistent back pain led to her myeloma diagnosis and why she now raises awareness to help others recognize subtle warning signs.

Patients with prostate cancer can position themselves to receive the best care possible by being seen by a multidisciplinary team of healthcare providers.

After surviving testicular cancer, I learned to let go of envy, live in the moment, and embrace gratitude by staying true to who I am.

Dr. Sandip Patel discusses findings from a real-world study of biomarker testing in early-stage resected non-small cell lung cancer in the U.S.

Enhertu significantly improved invasive disease-free survival when compared with Kadcyla in high-risk HER2-positive early breast cancer.

Dr. Patrick J. Hensley shares the treatment landscape of non-muscle-invasive bladder, as well as how individual risk factors can alter treatment options.

Dr. Patrick Wen discussed with CURE how Modeyso treats diffuse midline glioma, and what unmet needs remain for patients now that the therapy is available.